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Study protocol: The optimal feeding for preterm infants during the first weeks is still 
debated, especially when mother’s own milk is lacking or limited. Intact bovine colostrum 
(BC) contains high amounts of protein, growth factors, and immuno-regulatory compo-
nents that may benefit protein intake and gut maturation. We designed a pilot study to 
investigate the feasibility and tolerability of BC as the first nutrition for preterm infants. 
The study was designed into three phases (A, B, and C) and recruited infants with birth 
weights of 1,000–1,800 g (China) or gestational ages (GAs) of 27 + 0 to 32 + 6 weeks 
(Denmark). In phase A, three infants were recruited consecutively to receive BC as a 
supplement to standard feeding. In phase B, seven infants were recruited in parallel. In 
phase C (not yet complete), 40 infants will be randomized to BC or standard feeding. 
Feeding intolerance, growth, time to full enteral feeding, serious infections/NEC, plasma 
amino acid profile, blood biochemistry, and intestinal functions are assessed. This paper 
presents the study protocol and results from phases A and B.
results: Seven Danish and five Chinese infants received 22 ± 11 and 22 ± 6 ml·k-
g−1·day−1 BC for a mean of 7 ± 3 and 7 ± 1 days which provided 1.81 ± 0.89 and 
1.83 ± 0.52 g·kg−1·day−1 protein, respectively. Growth rates until 37 weeks or discharge 
were in the normal range (11.8 ± 0.9 and 12.9 ± 2.7 g·kg−1·day−1 in Denmark and China, 
respectively). No clinical adverse effects were observed. Five infants showed a transient 
hypertyrosinemia on day 7 of life.
Discussion and conclusion: The three-phased study design was used to proceed 
with caution as this is the first trial to investigate intact BC as the first feed for preterm 
infants. BC supplementation appeared well tolerated and resulted in high enteral protein 
intake. Based on the safety evaluation of phases A and B, the randomized phase C has 
Abbreviations: BC, bovine colostrum; DM, donor milk; FWCH, Foshan Women’s and Children’s Hospital; GA, gestational age; 
HH, Hvidovre Hospital; IF, infant formula; Ig, immunoglobulin; MM, mother’s own milk; NEC, necrotizing enterocolitis; RH, 
Rigshospitalet; SBMCH, Shenzhen Baoan Maternity and Child Healthcare Hospital.
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inTrODUCTiOn
Preterm birth (birth <37 weeks gestation) occurs in 10% of all 
pregnancies worldwide. Preterm infants suffer from various organ 
immaturities that may predispose them to immediate or later 
diseases. Adequate nutrient uptake and growth rates are required 
for very preterm infants to adapt well to postnatal life, but rapid 
enteral feeding is often difficult because the gastrointestinal tract 
is immature. Consequently, a suboptimal milk diet may lead to 
feeding intolerance, serious gastrointestinal complications (e.g., 
necrotizing enterocolitis, NEC), and late-onset sepsis (1).
Mother’s own milk (MM) is considered the optimal nutrition 
for preterm infants, and it is superior to infant formula (IF) in 
stimulating intestinal maturation, minimizing feeding intoler-
ance, reducing the risk of NEC and infections, and improving 
long-term neurodevelopment (1). However, MM is sometimes 
not present in sufficient amounts or unavailable during the first 
days after preterm delivery. IF may be given as the first diet to 
supplement MM feeding, if donor milk (DM) is not available. 
Still, DM may remain less effective than MM to stimulate growth, 
secure adequate nutrient intake, and provide protection against 
NEC and infections (2–4). DM usually consists of pasteurized 
mature human milk (HM) obtained from mothers at a relatively 
late stage in lactation after giving birth at term. This means that 
DM contains a reduced amount of protein and bioactive compo-
nents (5–7). DM is therefore not an ideal replacement for the first 
milk of the mother, the colostrum.
Bovine colostrum (BC) is the first milk from cows after birth, 
and we suggest that BC may be used to supplement MM during 
the first days of life, instead of IF or DM. BC is a rich source of pro-
tein and bioactive components, including lactoferrin, lysozyme, 
lactoperoxidase, immunoglobulins (Igs), as well as various 
growth factors (8, 9). Still, a number of nutritional characteristics 
of BC and milk differ from those in human colostrum (HC) and 
milk (e.g., levels of casein, whey proteins, oligosaccharides, and 
lactose). A number of phase I studies in human volunteers and 
phase II/III studies in patients have demonstrated a therapeutic 
potential of BC in gastrointestinal disorders (10). The safety and 
tolerability of BC has been tested in Danish pediatric patients 
subjected to intestinal resection (11) and chemotherapy for 
leukemia (NCT01766804). In a well-established piglet model of 
preterm infants (12), BC has repeatedly been shown to have ben-
eficial effects in stimulating gut functions and resistance against 
NEC, relative to IF (13). When compared with DM and IF, BC 
promoted better postnatal growth, decreased diarrhea incidence, 
and increased brush border lactase activity in piglets (14). It is 
not yet clear, if the inferior quality of IF for preterm infants is 
due to its extensive industrial processing (e.g., heat treatment 
and fractionation) or suboptimal products (e.g., hydrolyzed whey 
proteins, vegetable carbohydrates, and vegetable oils). A general 
immunological hypersensitivity to bovine proteins in IF for pre-
term infants is unlikely, considering the overall low prevalence of 
cow’s milk allergy in infants (2–3%) (15).
On this background, we hypothesized that it may be feasible 
and justifiable to use intact BC as a supplement to MM during 
the first days of life, instead of DM or IF. Since BC has never 
been used as the first feed for preterm infants, we planned a 
three-phased pilot study to test the feasibility and tolerability in 
different clinical settings. The objectives of the pilot study were 
(1) to obtain the first information on whether BC used as the first 
nutrition is feasible and tolerable in preterm infants born between 
1,000 and 1,800 g or 27 + 0 and 32 + 6 weeks’ gestational age 
(GA); (2) to help determine primary endpoints and sample size 
for a later, large randomized, controlled trial. Here, we report the 
entire study protocol and the results of the first two phases.
METHODS
Study Design
Since this was the first time BC was given as the initial nutrition 
to preterm infants, the pilot study was designed into three phases 
(A, B, and C) to proceed cautiously (Figure 1). Furthermore, the 
study was performed in two countries with very different clinical 
settings to test the feasibility of giving the intervention both in a 
clinical setting with access to DM and early enteral feeding, and in 
a setting with no access to DM with later introduction of enteral 
feeding, representing the normal spectrum of enteral feeding 
practices across the world (16). In phases A and B, a stepwise, 
single-group design was used. Reconstituted BC was given as the 
first supplementary diet to MM for no longer than 10 days post-
natal age. In phase A, three infants were included. Out of safety 
considerations, one infant was recruited and followed until he/
she reached full enteral feeding and a weight gain of 15 g·day−1, 
before the next infant was recruited. Since no safety concern was 
raised in phase A, phase B was initiated, in which seven infants 
were recruited and studied in parallel. In phase C, a randomized, 
open labeled, and controlled trial design will be used. BC will be 
compared with the currently used supplementary diets to MM 
(IF and DM).
Study Sites
Two Chinese hospitals, Foshan Women’s and Children’s Hospital 
(FWCH, Foshan) and Shenzhen Baoan Maternity and Child 
Healthcare Hospital (SBMCH, Shenzhen), and two Danish hos-
pitals, Rigshospitalet (RH, Copenhagen) and Hvidovre Hospital 
(HH, Copenhagen) participate in this pilot study. SBMCH and 
HH will only include patients for the randomized phase C.
been initiated. When complete, the Precolos trial will document whether it is feasible to 
use BC as a novel, bioactive milk diet for preterm infants. Our trial paves the way for a 
larger randomized controlled trial on using BC as the first feed for preterm infants with 
insufficient access to mother’s own milk.
Keywords: preterm infants, bovine colostrum, early enteral nutrition, protein intake, milk
FigUrE 1 | Design of the three-phased Precolos pilot study. BC is fed 
as the supplement (black boxes) when mother’s own milk is insufficient, 
instead of feeding donor milk (RH and HH) or infant formula (FWCH and 
SBMCH), according to local guidelines. In phase A, BC was given to three 
infants consecutively, i.e., each infant was followed until it reached full enteral 
feeding, and weight gain was 15 g·day−1 before the next infant was included. 
In phase B, BC was given to seven infants recruited in parallel. Phase C will 
be a randomized controlled trial (not yet completed). Due to differences in the 
normal progression of enteral feeding among hospitals, the BC intervention 
period was up to postnatal day 10 at RH and HH and will be up to postnatal 
day 14 for FWCH and SBMCH in phase C. BC, bovine colostrum; BW, birth 
weight; FWCH, Foshan Women’s and Children’s Hospital; GA, gestational 
age; HH, Hvidovre Hospital; PMA, postmenstrual age; RH, Rigshospitalet; 
SBMCH, Shenzhen Baoan Maternity and Child Healthcare Hospital.
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inclusion Criteria
Inclusion criteria differ between the countries to reflect local 
clinical conditions.
•	 FWCH and SBMCH:
 ◦ Preterm infants with birth weights between 1,000 and 
1,800 g
 ◦ Inclusion before first feed
•	 RH and HH:
 ◦ Preterm infants with GA between 27 + 0 and 32 + 6 wks
 ◦ Inclusion before 24 h of age
•	 Both sites
 ◦ Delivered at the study site or transferred from other hospi-
tals within 24 h after birth
 ◦ Signed parental consent
Exclusion Criteria
•	 Major congenital anomalies or birth defects
•	 Congenital infection
•	 Perinatal asphyxia (umbilical or first neonatal pH ≤ 7.0)
•	 GA at birth <28 weeks (FWCH and SBMCH)
•	 Extremely SGA infant (weight SD score <−3 SD)
•	 Need for invasive mechanical ventilation or cardiovascular 
support before first BC feed
recruitment and randomization
When a preterm infant was delivered, or transferred from other 
hospitals on the day of birth, attending neonatologists or a 
clinical researcher would evaluate the infant for its eligibility. If 
the infant fulfilled the recruitment criteria, the parent(s) would 
receive written and oral information about the study. Infants were 
included in the study after written parental consent was given.
Preterm infants were included in this study since we could not 
study the effect of BC as the first enteral nutrition for preterm 
infants by including other patient populations. Parents were 
informed with great care and given consideration time before 
inclusion. Because inclusion had to be done within a fixed period 
of time, this consideration time was not unlimited. If the parents 
found the consideration time to be too short, we accepted this and 
did not ask for consent.
No randomization was needed for phases A and B. For phase 
C, recruited infants are randomized into a control group and an 
intervention group in a 1:1 ratio. Random sequences of groups 
are generated by a computer program with randomly permuted 
blocks of sizes 2 and 4, written on slips, and put in opaque 
envelopes individually by an employee of the study sponsor. An 
envelope can only be opened to see the allocation after an infant 
has been enrolled. If multiple births are recruited together, all of 
them will be allocated to the same group, which will be accounted 
for during the data analysis. A set of 20 envelopes with random 
sequences will be generated for RH and HH together and coor-
dinated by the primary investigator (PI) of RH via telephone call, 
and the recruitment will stop when 20 infants in total have been 
enrolled. The PI of HH will call the PI of RH when an infant is 
recruited and the PI of RH will open the corresponding envelope 
and tell which group the infant should be randomized to. For 
FWCH and SBMCH, two sets of 20 envelopes will be generated 
(one set for each) due to the difficulties related to coordination 
by telephone conversation. The study sponsor will coordinate and 
stop recruitment at the two Chinese sites when 20 infants in total 
have been enrolled.
BC intervention
The BC used in the study was prepared by mixing BC powder 
with cooled boiled water at room temperature (10 g powder in 
50  ml water, 81kcal/100 mL). The BC powder was made from 
unmodified intact colostrum collected from healthy Danish dairy 
cows, obtained from the first and second milking after parturi-
tion. The BC was pasteurized (62.5°C for 30 min) and spray dried 
(ColoDan, Biofiber Damino, Gesten, Denmark). Reconstituted 
BC was kept in a refrigerator (4°C) for no more than 24 h. Prior 
to each feeding, the required amount of BC was warmed to 37°C 
in a water bath. The macronutrient and amino acid compositions 
of reconstituted BC are shown in Table 1 and are compared with 
that of HC, mature HM, and preterm IF.
nutritional guidelines at rH and HH 
(Denmark)
All recruited infants were fed according to the nutritional 
guidelines for preterm infants at each site. At RH and HH, the 
ESPGHAN nutritional recommendations are generally followed 
(19). Enteral nutrition was introduced as soon as possible after 
birth (usually within 2–6 h) and for infants of more than 28 weeks 
GA, volumes were increased as much as the infants tolerated. 
Parenteral nutrition (PN) was provided from the first day of life 
to infants with a BW below 1,000 g and/or GA less than 28 weeks. 
TaBlE 1 | Macronutrient and amino acid compositions of human 
milk (HM), human colostrum (HC), and bovine colostrum (BC), and 
recommendations (17) for the concentrations of nutrients in preterm 
infant formula.
HMa HCa BCb lSrO/aSnS
Carbohydrate (g·l−1) 67–78 44–59 33 9.6–12.5 (g·100kcal–1)
Lipid (g·l−1) 32–36 20–29 35 4.4–5.7 (g·100kcal–1)
Protein (g·l−1) 9–12 11–32 83 2.5–3.6 (g·100kcal–1)
Whey (g·l−1) 6–7.2 4.3–11.1 57
Casein (g·l−1) 4–4.8 3.0–5.6 26
amino acids (mg·g−1 protein)
Cysteine 20 40 16 34c
Histidine 23 23 26 21
Isoleucine 53 36 44 52
Leucine 104 91 90 102
Lysine 71 59 73 73
Methionine 16 13 19 See cysteine
Phenylalanine 37 43 45 78c
Threonine 44 55 59 45
Tryptophan ND NDa 19 15
Tyrosine 46 44 54 See phenylalanine
Valine 51 54 63 53
Arginine 36 55 41 29
LSRO, Life Sciences Research Organization; ASNS, American Society for Nutritional 
Sciences.
aValues are based on Ref. (9, 18, 20); ND, not determined in the reference study.
bCarbohydrate, lipid, and amino acid compositions were calculated based on the 
product specifications of ColoDan BC powder provided by Biofiber Damino (Gesten, 
Denmark). Levels of whey and casein were measured at Department of Food Science 
(University of Copenhagen) by Milkoscan (FOSS, Hilleroed, Denmark) before and after 
casein removal.
cMethionine and cysteine, and phenylalanine and tyrosine are listed in combination. 
The ratio of each of these combinations of amino acids should not exceed 2:1 or 1:2 
without appropriate testing for adequacy.
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Older infants did generally not get any PN. Full enteral feeding 
was defined as 160 ml·kg−1·day−1, and PN was used until the infant 
received ~90% of this volume. MM was the first choice of milk 
and only supplemented if not available in adequate amounts. 
Infants were supplemented with DM in the first weeks of life, 
before switching to IF (Enfalac Preterm Formula; Mead Johnson 
Nutritionals, Nijmegen, Netherlands). Fortification (Enfamil 
Human Milk Fortifier, Mead Johnson Nutrition) of MM and 
DM normally began when infants could take 140 ml·kg−1·day−1 
enterally.
Nutritional Guidelines at FWCH and SBMCH (China)
At FWCH and SBMCH, feeding was normally initiated within 
48 h after birth with a volume of 5–10 ml·kg−1·day−1 and advanced 
with a rate of 10–20  ml·kg−1·day−1. The volume of full enteral 
feeding was defined as 120  ml·kg−1·day−1, and supplementary 
PN was used until infants reached this volume. When MM 
was absent, or not available in adequate amounts, IF (SSC 81; 
Abbott Laboratories, Abbott Park, IL and Enfamil A+, Mead 
Johnson) was used. Fortification (Similac Human Milk Fortifier, 
Abbott Nutrition) of MM began when the infants could take 
80 ml·kg−1·day−1 enterally.
BC Regimen
In phases A and B, BC was given as a supplement to MM to 
infants instead of DM (at RH) or IF (at FWCH) until postnatal 
day 10. The volume of BC fed each day was determined by the 
expected enteral feeding volume according to the above described 
nutritional guidelines at each hospital and the volume of MM 
available. Importantly, the volume of BC intervention together 
with available MM was not allowed to exceed a volume equivalent 
to 4.5  g·kg−1·day−1 protein, e.g., the upper protein intake limit 
according to ESPGHAN (19). When calculating the amount of 
protein provided by MM, 20 g·l−1 was used as the estimated con-
centration since preterm milk usually contains a higher amount 
of protein than normal term milk and out of safety concerns, we 
did not want to risk an underestimation of the protein intake 
from MM (20). If the available amount of MM, and the maximal 
volume of BC supplementation (due to protein limitations), could 
not meet the expected enteral feeding volume, DM (at RH) or IF 
(at FWCH) was given to fulfill the needs. After the intervention 
period, the infants received the standard enteral diets. In phase 
C, 40 infants will be randomized into two groups, an intervention 
group and a control group. Infants in the intervention group will 
receive BC, as described for phases A and B, and infants in the 
control group will receive the respective standard diets at each 
site. Infants in both groups will receive standard diets after the 
intervention period.
Outcome Measures
Demographic Characteristics of the Study 
Population
Major obstetrical risk factors were registered. Moreover, GA, 
birth weight, length and head circumference, gender, Apgar 
scores, inborn or transferred, days of mechanical ventilation, and 
days of extra oxygen were registered.
Clinical Outcomes
To determine the safety and tolerability of BC feeding, clinical 
outcomes were recorded. They included the presence of feeding 
intolerance (defined as at any time when feeding was withheld 
by the neonatologists from day 1–7 and from day 8–14), char-
acteristics of gastric residuals, stool characteristics (all measured 
daily for the first 2  weeks), and any suspicion or treatment of 
NEC. Furthermore, bronchopulmonary dysplasia, retinopathy 
of prematurity, intraventricular hemorrhage, and periventricular 
leukomalacia diagnosed at discharge were recorded. Growth and 
nutritional data including weekly anthropometric measures 
[body weight (BWT), length, and head circumference], days to 
regain birth weight, days on PN, time to full enteral feeding, and 
nutritional intake were also recorded. In phases A and B, time to 
full enteral feeding was defined according to the guideline of each 
hospital, i.e., as the first day an infant received 160 ml·kg−1·day−1 
at RH, or 120 ml·kg−1·day−1 at FWCH for a consecutive period 
of 72  h. Based on the experiences from phases A and B, full 
enteral feeding volume will be defined as 150 ml·kg−1·day−1 for 
all sites in phase C to have a uniform definition.
Paraclinical Outcomes
In phases A and B, safety measures including plasma amino 
acid composition, routine blood biochemistry tests, and levels 
of intact bovine IgG (bIgG) in plasma were measured on days 
7 ±  1 and 14 ±  1. Intact bIgG molecules were quantified by 
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electroimmunoassay (lower detection limit, 5  μg·ml−1) using 
purified bIgG as the standard and anti-bIgG as the antibody 
at Department of Biology, Lund University (21). In phase C, 
in addition to the above mentioned blood tests, a simplified 
three-sugar test will be performed on study day 7 ± 1 to assess 
intestinal function. In brief, an oral bolus containing 5% lactose, 
5% lactulose, and 2% mannitol will be given to the study subjects. 
Blood samples will be taken at 40 min, and urine samples will be 
collected continuously for 6 h after administration. By analyzing 
the level of galactose (a digestive adduct of lactose) in blood and 
the ratios of lactulose/lactose and lactulose/mannitol in urine, 
lactose digestion, galactose uptake capacity, and intestinal perme-
ability can be evaluated (22, 23). Fecal samples are collected on 
days 7 ± 1 and 14 ± 1 for fecal microbiota and short-chain fatty 
acid composition analyses in all three phases of the study.
Sample Size
Fifty infants are planned to be recruited in the study: 3 in phase A, 
7 in phase B, and 40 (20 + 20) in phase C. Since this study is a pilot 
feasibility study and no primary endpoint was set, the sample size 
was determined by practical considerations.
Statistical analysis
Phases A and B
Continuous variables were presented as means ± SD, and binary 
data were presented in counts. BUN levels measured on two 
different time points were compared for each hospital using 
paired t-test in Prism 5 (version 5.01, GraphPad software). Two 
types of growth velocity (GV) were calculated based on BWT 
measured weekly according to the following formulas: (1) GV 
(g·day−1) = (BWTDay n − BWTDay 1)/(Day n − Day 1) and (2) 
GV (g·kg−1·day−1) = [1,000 × ln(BWTDay n/BWTDay 1)]/(Day 
n − Day 1) (24). Z-score was calculated based on GA and weight 
using a gender specific reference (25) at birth and at 37 weeks 
or discharge. Day of regaining birth weight was recorded or 
calculated based on GV if not recorded.
Randomized Phase C
Outcomes from phase C will be compared for Denmark and 
China separately. Outcomes between BC group and the control 
group will be compared without knowing the group designation 
code. Continuous outcomes, e.g., levels of plasma amino acids, 
will be compared using general linear models with adjustment 
for potential confounders, e.g., birth weight, GA, study site, and 
gender. Data will be checked for normality and homoscedasticity 
and will be transformed when required. For binary outcomes, 
e.g., presence of feeding intolerance, generalized linear models 
will be used with adjustment for potential confounders. p < 0.05 
is considered as statistically significant.
Handling of Personal Data
This research project was registered at Datatilsynet (Danish Data 
Protection Agency). Personal data are treated with respect and 
will  be handled according to local regulations. The outcome-
related information from patient records is transferred into case 
report forms, if the participants’ parents give consent. Participants’ 
data collected during the study, including the data from the 
participants’ mothers, can be reviewed by the study sponsor, 
good clinical practice (GCP) monitor or people from the Danish 
authorities, who are obligated to keep the data confidential by law.
Safety Considerations and Monitoring
Severe adverse effects (any cases of surgical NEC and death) and 
severe unexpected suspected adverse effects are reported to rel-
evant ethics committees. Other severe adverse effects and several 
outcome measures indicating safety and tolerability of BC feeding 
(e.g., presence of feeding intolerance, characteristics of gastric 
residual, plasma amino acid composition, plasma bIgG level, 
and routine blood biochemistry tests) are regularly evaluated by 
neonatologists, clinical research staff, principal investigators at 
each site, as well as the study sponsor. Safety reports including 
above mentioned safety and tolerability data were evaluated by a 
data safety monitoring board (DSMB) after completion of phases 
A and B, respectively. DSMB consisted of three persons with 
expertise in neonatology, statistics, and methodology of clinical 
trials. Since Precolos was a pilot study, there were no defined stop 
rules. In case of severe unexpected, suspected adverse reactions, 
or other evidence of harm, termination of the study was consid-
ered by discussion between attending neonatologists, clinical 
research staff, principal investigators, study sponsor, and DSMB. 
The study sponsor ensured the GCP monitoring, according to a 
guideline based on the GCP guideline of International Council 
for Harmonization.
Ethical approval
The study protocol was approved by the Committees on Health 
Research Ethics in the Capital Region of Denmark and the Ethical 
Committees of Clinical Trials at FWCH and SBMCH.
iniTial rESUlTS (PHaSES a anD B)
Clinical Characteristics
Twelve infants were included in phases A and B; seven were from 
RH and five from FWCH (Table 2). The last inclusion was a set 
of triplets (RH) which meant that we included 12 infants in total 
rather than the planned 10. Mothers of three infants (two RH and 
one FWCH) had premature rupture of membranes >24  h. No 
other obstetrical complications (i.e., chorioamnionitis, placental 
abruption, placenta previa, preeclampsia, or eclampsia) were 
recorded. Apgar scores at 5 min were 10 for all infants.
nutrition and Clinical Outcomes at Danish 
Site (rH)
Bovine colostrum was given as the first diet on day 1 for a total of 
7 ± 3 days, amounting to a total volume of 273 ± 199 ml (Table 3). 
During the days, BC was given, 22 ± 11 ml·kg−1 was fed provid-
ing 1.81 ±  0.89  g·kg−1 protein per day. Two infants with birth 
weights <1,000  g received parenteral nutrition for 11–13  days, 
but the remaining infants received only enteral nutrition. During 
the first week of life, the infants received 97 ml·kg−1·day−1 fluid, 
3.4  g·kg−1·day−1 protein, and 69  kcal·kg−1·day−1. BC accounted 
for on average 23% of fluid, 54% of protein, and 26% of energy 
TaBlE 3 | Outcomes of the first infants to receive BC as supplement to 
maternal milk in the first days of life.a
rH FWCH
N 4–7 4–5
Days on PN (days) 3 ± 6 22 ± 9
BC feeding (days) 7 ± 3 7 ± 1
Total BC intake (ml) 273 ± 199 234 ± 92
TTF160 (days) 22 ± 11 ND
TTF120 (days) 8 ± 3 21 ± 8
FI in week 1, n 6 1
FI in week 2, n 1 0
GR in week 1 (ml) 80 ± 41 5 ± 5
Body weight at 37 weeks/discharge (g) 2,492 ± 326 2,138 ± 176
GA at 37 weeks/discharge (weeks) 37.3 ± 0.5 35.9 ± 0.8
Z-score at 37 weeks/discharge −1.3 ± 0.7 −1.3 ± 0.6
Z-score change −1.2 ± 0.6 −0.5 ± 0.5
GV (g·day−1) 22.0 ± 4.6 23.1 ± 5.0
GV (g·kg−1·day−1) 11.8 ± 0.9 12.9 ± 2.7
Regain birth weight (days) 12 ± 2 6 ± 2
Hypertyrosinemia on day 7, n 3 2
Tyrosine on day 7 (μmol·l−1) 171 ± 200 197 ± 163
BUN on day 7 (mmol·l−1) 5.8 ± 3.3 3.3 ± 1.1
BUN on day 14 (mmol·l−1) 2.0 ± 0.3 1.7 ± 0.6
BC, bovine colostrum; BUN, blood urea nitrogen; FI, feeding intolerance; FWCH, 
Foshan Women’s and Children’s Hospital; GA, gestational age; GR, gastric 
residual; GV, growth velocity; HC, head circumference; PN, parenteral nutrition; RH, 
Rigshospitalet; TTF160, time to reach enteral feeding at 160 ml·kg−1·day−1; TTF120, 
time to reach enteral feeding at 120 ml·kg−1·day−1.
aUnless otherwise indicated, values are given as means ± SD.
TaBlE 2 | neonatal characteristics of the studied infants recruited in 
phases a and B at each hospital.a
rH FWCH
N 7 5
GA (weeks) 29.6 ± 1.6 31.8 ± 1.6
Birth weight (g) 1,346 ± 344 1,526 ± 222
Birth Z-score −0.15 ± 0.31 −0.72 ± 0.42
Birth length (cm) 38.9 ± 3.3 42.8 ± 2.4
Birth HC (cm) 27.4 ± 3.0 27.4 ± 2.4
Male gender, n 3 2
Antenatal steroids, n 5b 2
C-section, n 6 1
C-section, cesarean section; FWCH, Foshan Women’s and Children’s Hospital, China; 
GA, gestational age; HC, head circumference; RH, Rigshospitalet, Denmark.
aUnless otherwise indicated, values are given as means ± SD.
bFor two infants, there was no information about antenatal steroid treatment.
6
Li et al. BC for Preterm Infants
Frontiers in Pediatrics | www.frontiersin.org March 2017 | Volume 5 | Article 42
intakes, with the remaining deriving from MM, DM, and par-
enteral nutrition (Figure 2). In week 2, fluid and energy intakes 
increased to 161 ml·kg−1·day−1 and 114 kcal·kg−1·day−1, whereas 
protein intake remained the same as in week 1 (Figure 2). Time 
to regain birth weight was 12 ±  2 days, and time to reach full 
enteral feeding (160 ml·kg−1·day−1) was 22 ±  1 (Table 3). Four 
RH infants received 150–160 ml·kg−1·day−1 for a relatively long 
period. When 150 ml·kg−1·day−1 was used as the cut-off, the time 
was only 9 ± 3 days. GV was negative in the first week, increased 
throughout weeks 2–3 and decreased in week 4 (Figure  2). 
Feeding intolerance was observed in six infants during the first 
week and in one infant in week 2. Total volume of gastric residu-
als was 80 ± 41 ml (10.8% of enteral nutrition) in the first week 
(Table 3).
nutrition and Clinical Outcomes at 
Chinese Site (FWCH)
Bovine colostrum was given as the first diet on days 2–3 for a 
total of 7 ± 1 days, amounting to a total volume of 234 ± 92 ml 
(Table 3). During the period when BC was given, 22 ± 8 ml·kg−1 
was fed providing 1.83 ±  0.52  g·kg−1 protein per day. BC was 
used as the sole enteral nutrition for the first days since MM 
was not available for the infants, and parenteral nutrition was 
used for 22 ±  9  days (Table  3). During the first week of life, 
infants at FWCH received 91 ml·kg−1·day−1 fluid, 2.7 g·kg−1·day−1 
protein, and 67  kcal·kg−1  day−1 with BC accounting for 16, 46, 
and 18% of total fluid, protein, and energy intake. In week 2, 
fluid, protein, and energy intakes increased to 153 ml·kg−1·day−1, 
3.7  g·kg−1·day−1, and −115  kcal·kg−1·day−1 (Figure  2). Time to 
regain birth weight was 6 ± 2 days, and time to reach full enteral 
feeding (120 ml·kg−1·day−1) was 22 ± 11 (Table 3). As in Denmark, 
GV was negative in the first week, increased throughout weeks 
2–3 and decreased in week 4 (Figure 2). Feeding intolerance was 
observed in one infant during the first week and none in week 2. 
Total volume of gastric residuals was 5 ± 5 ml at FWCH (1.3% 
of enteral nutrition) in the first week (Table 3).
Safety Outcomes
No clinical adverse reactions from feeding BC were observed. 
No infants were diagnosed with NEC, sepsis, meningitis, 
bronchopulmonary dysplasia, retinopathy of prematurity, and/
or periventricular leukomalacia, but three (two at RH and one at 
FWCH) were diagnosed with grade 1 intraventricular hemorrhage. 
At RH, the levels of blood urea nitrogen were 5.8 ± 3.3 mmol·l−1 
on day 7 ± 2 and decreased to 2.0 ± 0.3 mmol·l−1 on day 14 ± 2 
(p < 0.05, Table 3). At FWCH, BUN levels were 3.3 ± 1.1 mmol·l−1 
on day 7 ± 2 and decreased to 1.7 ± 0.6 mmol·l−1 at FWCH on 
day 14 ±  2 (p <  0.01). Amino acid levels were within normal 
clinical ranges, apart from five cases of hypertyrosinemia on day 
7 (Table 3), that returned to normal on day 14. All levels of bIgG 
were below the assay detection limit.
DiSCUSSiOn
Precolos is a pilot feasibility study that will provide information 
on feasibility, tolerability, and potential effects of BC as the first 
feeding for very preterm infants. Since this is the first study 
to feed intact BC as the initial supplemental diet for preterm 
infants, we designed a three-phased, stepwise study to allow 
close monitoring of participants for possible adverse reactions 
to BC feeding. The BC product used for this study was pro-
duced by gentle pasteurization and spray drying of intact BC. 
Milk processing, especially pasteurization, usually reduces the 
concentration of bioactive proteins, but pasteurized and raw BC 
showed similar NEC-protective effects in preterm pigs, relative 
to IF (26). A  recent randomized, controlled trial investigated 
BC for preterm infants (27), but the product used (Pedimune, 
Merck India, Mumbai, India), contained only 23% colostrum, 
and the major macronutrient was carbohydrate (73%, source 
FigUrE 2 | intake of fluid (a), protein (B), and energy (C) from different 
nutritional sources during the first 2 weeks of life, and growth velocity 
during the first 4 weeks of life, expressed as grams per day (D) and 
grams per kilogram per day (E). FWCH, Foshan Women’s and Children’s 
Hospital; RH, Rigshospitalet. Panels (a–C) show values for bovine colostrum 
(BC, black bars), mother’s own milk (MM, light gray bars), human donor milk 
(DM, light gray bars with hatching), infant formula (IF, dark gray bars), human 
milk fortifier (HMF, dark gray bars with hatching), and parenteral nutrition (PN, 
white bars). Panels (D,E) show values for RH (white circles) and FWCH (black 
circles). Values are presented as mean ± SEM for RH (n = 6–7) and FWCH 
(n = 4–5).
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not specified). The product was dissolved in HM (60–67  g in 
100 ml) and given to preterm infants at a dose of 2–3 ml four 
times a day. The study was underpowered for its endpoint but 
indicated that feeding this product was associated with more 
radiographic signs of NEC. Since a mixed product with carbo-
hydrate as the main ingredient was used, it is difficult to compare 
the results with those in this trial. Previous experimental studies 
indicate that milk processing and addition of carbohydrate 
(typically vegetable-based maltodextrins) may induce NEC (28). 
Potentially, high osmolality may also add inflammatory damage 
to the immature gut (29). We suggest that mildly processed, 
intact BC may be a better diet for the early feeding of preterm 
infants. We also think that such an intervention deserves careful 
testing in larger clinical trials.
The first 12 preterm infants in the world have now received 
intact BC as a supplement to MM during the first days of life. 
The high level of protein in BC might be an advantage, as the 
same volume of BC can supply about eight times more protein 
than HM and three times more than IF. For safety reasons, 
the maximal total protein intake was set at 4.5  g·kg−1·day−1 
according to the ESPGHAN guideline, and plasma amino acid 
and blood biochemistry values for liver and kidney functions 
were recorded to monitor the protein metabolism. As expected, 
BC provided about 50% of the protein during the first week in 
phases A and B, resulting in a mean intake of 3.1 g·kg−1·day−1, 
a level that is often difficult to reach at this early stage (30, 
31). Despite this, we still observed the common drop in weight 
Z-score from day 1 until a postmenstrual age of 37  weeks or 
discharge in these infants (32). Plasma amino acid levels were 
measured to monitor potential toxicity related to high protein 
intake. In phases A and B, a transient hypertyrosinemia was 
observed in five infants on days 6–8 when tyrosine levels nor-
mally reach a peak (33). Tyrosine levels returned to normal in 
all infants a week later. Prolonged high levels of tyrosine may 
be associated with later learning disability, as indicated from 
studies in term infants (34). IFs with a relatively high content 
of casein (60–80% of total protein) may also lead to increased 
phenylalanine and tyrosine levels (35). The casein intake was 
0.6  g·kg−1·day−1, which was much less than that in the study 
referred above (1.4–1.9  g·kg−1·day−1) (35). Relative concentra-
tions of phenylalanine and tyrosine in BC were similar to those 
in HM, and we did not observe elevated levels of phenylalanine. 
Thus, the blood biochemistry results did not raise any concerns 
of toxicity related to excessive protein intake. After consulting 
with our DSMB, we decided to continue with phase C where 
it will be possible to compare tyrosine levels in the BC group 
with those in a control group.
Immunoglobulins, and especially IgGs, are abundant proteins 
in reconstituted BC and accounted for more than 30% of the 
total dietary protein in our study. For calves, colostrum provides 
most of the circulating IgG for passive immunity, while in human 
infants, this IgG is mainly transferred across the placenta before 
birth. We measured bIgG in plasma to check if intact bovine 
proteins (e.g., IgG, casein, and β-lactoglobulin) would cross the 
immature intestinal epithelium in preterm infants. This might 
sensitize the immune system and thereby predispose to NEC 
in preterm infants (36–38), although a direct (immunologi-
cal) link between cow’s milk protein and NEC has never been 
documented. The prevalence of cow’s milk allergy is only 2–3% 
in normal infants (15) and may be even lower in preterm infants 
with an immature immune system. In phases A and B, we did 
not find any detectable levels of bIgG in plasma, probably reflect-
ing a relatively high integrity of the intestinal epithelium in the 
studied preterm infants. 
We decided to study BC supplementation in Denmark and 
in China to test its feasibility under very different conditions 
where access to DM was one of the differences in clinical care. 
The hospitals also had different conditions for determining GA, 
so to be cautious we used different age/weight inclusion criteria 
for the two sites, and we did not consider this compromising for 
the main aims of the study. In Denmark, mothers stayed in the 
wards with their infants and the infants therefore had a higher 
chance to receive considerable amounts of MM than those at 
the Chinese sites. When high amounts of MM were available, 
infants only received small amounts of BC, probably less than 
the amount required to demonstrate its potential benefits or 
harm. In China, fewer babies had access to MM, thereby pro-
viding better conditions to study effects/harms of BC feeding. 
Potentially, differences in intake of MM at the study sites need to 
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be considered and adjusted for when analyzing the data from the 
later larger trials. On the other hand, it was judged important in 
this study to test supplementary BC feeding in different clinical 
settings to be able to predict the feasibility of performing a large 
multicenter randomized trial.
The Chinese sites and Danish sites also differed in the feeding 
regimens according to their use of nutritional guidelines. The 
Chinese sites started enteral feeding within 48 h and increased 
the volume slowly by 10–20 to 120 ml·kg−1·day−1 as the target full 
enteral volume. The Danish site normally started enteral feeding 
within 2–6 h after birth and increased the volume as fast as the 
infants could tolerate to 160 ml·kg−1·day−1 as the full enteral vol-
ume. We did not consider it possible or appropriate to standardize 
the feeding regimens.
In conclusion, we suggest that BC may be a relevant alterna-
tive milk diet to DM or IF as a supplement to MM in the first 
days of life in preterm infants. The Precolos trial is the first step 
to document this novel method. If Precolos can demonstrate that 
early BC supplementation is well tolerated, feasible, and supports 
one or more of the multiple outcomes to be measured in phase 
C, then this paves the way for a larger randomized clinical trial. 
Clinically relevant outcomes of such a larger trial will be intestinal 
functions (e.g., feeding intolerance and intestinal permeability), 
time to full enteral feeding, growth, length of hospital stay, NEC, 
and sepsis.
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